Company Profile
Kura Oncology Stock Price, News & Analysis
- Ticker:
- KURA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.28 USD (+0.87%)
Close
Last updated: August 6, 2026
796M USD
Market cap
Why the stock is moving
The latest monitored company update is “Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Precision Oncology Company
Kura Oncology develops targeted therapies for genetically defined cancers.
KOMZIFTI
KOMZIFTI, or ziftomenib, is a menin inhibitor commercialized for relapsed or refractory NPM1-mutant acute myeloid leukemia.
Menin Biology
Ziftomenib disrupts the menin-KMT2A interaction that sustains leukemic gene expression in NPM1-mutant and KMT2A-rearranged AML.
Combination Development
Kura is evaluating ziftomenib with standard AML agents and across earlier treatment settings, seeking to establish it as a broadly combinable therapeutic backbone.
Future catalysts
Multiple ziftomenib clinical readouts across combination regimens and AML treatment settings are expected during 2026.
Recent news
- 01
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Kura Oncology
- 02
Kura Oncology to Report Second Quarter Financial Results
Source: Kura Oncology
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kura Oncology (KURA)?
Kura Oncology (KURA) most recently closed at 9.28 USD, a +0.87% move versus the previous session.
What is the market cap of Kura Oncology (KURA)?
Kura Oncology currently has a market capitalization of 796M USD on BioPharmSignal.
What does Kura Oncology do?
Precision Oncology Company Kura Oncology develops targeted therapies for genetically defined cancers. KOMZIFTI KOMZIFTI, or ziftomenib, is a menin inhibitor commercialized for relapsed or refractory NPM1-mutant acute myeloid leukemia. Menin Biology Ziftomenib disrupts the menin-KMT2A interaction that sustains leukemic gene expression in NPM1-mutant and...
On which exchange is KURA stock listed?
Kura Oncology (KURA) is associated with NASDAQ, United States, Biopharma.
What is ziftomenib?
Multiple ziftomenib clinical readouts across combination regimens and AML treatment settings are expected during 2026.
Which conditions is Kura Oncology targeting with ziftomenib?
Kura Oncology is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Kura Oncology describe recent progress with ziftomenib?
Multiple ziftomenib clinical readouts across combination regimens and AML treatment settings are expected during 2026.
What is Precision?
Precision Oncology Company Kura Oncology develops targeted therapies for genetically defined cancers.